natgillin/translations-raw huggingface dataset:
PIPERAZINES USEFUL FOR TREATING PAIN 
PIPERAZINI KORISNI ZA LIJEČENJE BOLI
Combinations comprising antimuscarinic agents and beta-adrenergic agonists 
KOMBINACIJE KOJE SADRŽE ANTIMUSKARINSKA SREDSTVA I BETA-ADRENERGIČKE AGONISTE
SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS 
SUPSTITUIRANI DERIVATI PIRIDO[2,3-D]PIRIMIDINA KORISNI KAO LIJEKOVI ZA LIJEČENJE AUTOIMUNIH BOLESTI
QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS 
KINOLINON-KARBOKSAMIDNI SPOJEVI KAO AGONISTI 5-HT4 RECEPTORA
-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY 
DERIVATI 4-FENIL-5-OKSO-1,2,4,5,6,7,8-HEKSAHIDROKINOLINA KAO LIJEKOVI ZA LIJEČENJE NEPLODNOSTI
ROOFING ASSEMBLY HAVING HIGH RESISTANCE FOR USE WITH ROOFS OF RESIDENTIAL AND INDUSTRIAL BUILDINGS 
KROVNI SKLOP KOJI IMA VELIKU OTPORNOST I KOJI SE PRIMJENJUJE ZA KROVOVE STAMBENIH I INDUSTRIJSKIH ZGRADA
METHOD AND APPARATUS FOR DETERMINING THE LOCATION OF A STATIONARY SATELLITE RECEIVER 
POSTUPAK I UREĐAJ ZA ODREĐIVANJE LOKACIJE STACIONARNOG SATELITSKOG PRIJEMNIKA
NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR 
NOVI PEPTIDI KOJI SE VEŽU NA ERITROPOETINSKI RECEPTOR
Treatment of fungal infections 
LIJEČENJE GLJIVIČNIH INFEKCIJA
METHOD AND MEANS FOR PRODUCING A MAGNETICALLY INDUCED INDICIA IN A COATING CONTAINING MAGNETIC PARTICLES 
POSTUPAK I SREDSTVA ZA IZRADU MAGNETSKI POTAKNUTIH OZNAKA U PREMAZU KOJI SADRŽI MAGNETSKE ČESTICE
A DAVIT ASSEMBLY AND A METHOD FOR MOVING A BOAT 
SKLOP SOHA I POSTUPAK ZA PREMJEŠTANJE ČAMCA
N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS 
SPOJEVI N-[({'4-SUPSTITUIRANOG PIPERAZIN-1-IL}SULFONILMETIL)ALKIL]-N-HIDROKSIFORMAMIDA KAO INHIBITORI METALOPROTEINAZE
KEY COMBINATION ELEMENT IN KEY BLANK AND KEY 
ELEMENT KOMBINACIJE KLJUČA U PRAZNOM KLJUČU I KLJUČ
IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING ACE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF 
POBOLJŠANA FARMACEUTSKA SMJESA KOJA SADRŽI ACE INHIBITOR I POSTUPAK ZA NJENO PRIPRAVLJANJE
NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 
NOVI INHIBITORI 17beta HIDROKSISTEROIDA DEHIDROGENAZE TIPA I
TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS 
TRIPEPTID I TETRAPEPTID SULFONI
INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS 
DERIVATI INDOZOLONA KAO INHIBITORI 11B-HSD1
NON STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS 
NESTEROIDNI MODULATORI GLUKOKORTIKOIDNOG RECEPTORA
OXALIPLATIN WITH A LOW CONTENT OF ACCOMPANYING IMPURITIES AND A METHOD FOR PREPARATION THEREOF 
OKSALIPLATIN S NISKIM SADRŽAJEM PRATEĆIH NEČISTOĆA I POSTUPAK NJEGOVOG DOBIVANJA
TAMPER RESISTANT DOSAGE FORM COMPRISING AN ADSORBENT AND AN ADVERSE AGENT 
OBLIK DOZIRANJA OTPORAN NA NEOVLAŠTENU PROMJENU KOJI SADRŽI ADSORBENT I SUPROTNI AGENS
SOLID FORMS OF THE MAGNESIUM SALT OF (S)-OMEPRAZOLE AND PROCESSES FOR THEIR PREPARATION 
KRUTE FORME MAGNEZIJEVE SOLI (S)-OMEPRAZOLA I POSTUPCI ZA NJIHOVU PRIPRAVU
Combinations comprising antimuscarininc agents and beta-adrenergic agonists 
KOMBINACIJE KOJE SADRŽE ANTIMUSKARINSKA SREDSTVA I BETA-ADRENERGIČKE AGONISTE
-HYDROXY TAMOXIFEN GEL FORMULATIONS 
FORMULACIJE 4-HIDROKSI TAMOKSIFEN GELA
SYNTHESIS OF DEOXYBIOTINYL HEXAMETHYLENEDIAMINE-DOTA 
SINTEZA DEOKSIBIOTINIL HEKSAMETILENDIAMIN-DOTA
Device and method for encrypting and decrypting a block of data 
UREĐAJ I POSTUPAK ZA ENKRIPCIJU I DEKRIPTIRANJE BLOKA PODATAKA
IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY 
IMIDAZOLINSKI DERIVATI SA CB1-ANTAGONISTIČKOM AKTIVNOSTI
PHENYL-PIPERAZIN METHANONE DERIVATIVES 
DERIVATI FENIL-PIPERAZIN METANONA
PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF BETA-ADRENERGIC RECEPTOR KINASE 1 
DERIVATI PIRAZOLOPIRIDINA KAO INHIBITORI KINAZE 1 BETA-ADRENERGIČNOG RECEPTORA
PERSONAL DOCUMENT IN FORM OF A BOOKLET 
OSOBNI DOKUMENTI U FORMI KNJIŽICE
CONCENTRATED LIQUID TRIAZOLE FUNGICIDE FORMULATIONS 
KONCENTRIRANI TEKUĆI TRIAZOL FUNGICIDNI PRIPRAVAK
MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES 
LIJEKOVI ZA LIJEČENJE ILI PREVENCIJU FIBROZNIH OBOLJENJA
Synergistic mixtures of anthranilamide invertebrate pest control agents 
SINERGISTIČKE SMJESE ANTRANILAMIDNIH SREDSTAVA ZA KONTROLU ŠTETOČINA BESKRALJEŽNJAKA
A PREFORM OF A PLASTIC CONTAINER PARTICULARLY FOR PACKAGING FOODSTUFFS 
PREDOBLIK PLASTIČNE POSUDE POSEBNO ZA PAKIRANJE HRANE
Method of reducing alpha, beta- unsaturated ketones in opioid compositions 
POSTUPAK REDUCIRANJA ALFA, BETA NEZASIĆENIH KETONA U OPIOIDNIM SASTAVIMA
ISOQUINOLINE DERIVATIVES 
IZOKINOLINSKI DERIVATI
Piperidine compounds and pharmaceutical compositions containing them 
SPOJEVI PIPERIDINA I FARMACEUTSKI SASTAVI KOJI IH SADRŽAVAJU
CONTROLLED RELEASE COMPOSITIONS FOR INTERFERON BASED ON PEGT/PBT BLOCK COPOLYMERS 
SASTAVI KONTROLIRANOG OTPUŠTANJA ZA INTERFERON KOJI SE TEMELJI NA PEGT/PBT BLOK KOPOLIMERIMA
COMBINATION TREATMENT FOR MULTIPLE SCLEROSIS 
KOMBINACIJSKO LIJEČENJE MULTIPLE SKLEROZE
ANIONIC HYDROGEL MATRICES WITH PH DEPENDENT MODIFIED RELEASE AS DRUG CARRIERS 
MATRICA ANIONSKOG HIDROGELA S PH OVISNIM MODIFICIRANIM OSLOBAĐANJEM KAO NOSAČ LIJEKA
METHOD AND APPARATUS FOR COLD JOINING FLANGES AND COUPLINGS ELEMENTS TO PIPES 
POSTUPAK I ALATI ZA HLADNO SPAJANJE PRIRUBNICA I SPOJNIH ELEMENATA NA CIJEVI
Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level 
KOMBINACIJSKA TERAPIJA ZA LIJEČENJE DIJABETESA I STANJA POVEZANIH S NJIM, TE ZA LIJEČENJE STANJA KOJA SE POBOLJŠAVAJU POVEĆANJEM NIVOA GLP-1 U KRVI
Controlled release compositions for interferon based on block polymers 
SASTAVI KONTROLIRANOG OTPUŠTANJA ZA INTERFERON KOJI SE TEMELJI NA PEGT/PBT BLOK KOPOLIMERIMA
UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS 
UREA ANTAGONISTI P2Y1 RECEPTORA KORISNI U LIJEČENJU TROMBOTIČKIH STANJA
OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS 
DERIVATI OKSADIAZOLONA KAO AGONISTI PPAR DELTA
HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS 
HIDANTOINSKI DERIVATI KORISNI KAO INHIBITORI METALOPROTEINAZA
,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS 
HETEROBICIKLIČKI INHIBITORI PROTEIN KINAZE SUPSTITUIRANI 6,6-BICIKLIČKIM PRSTENOM
PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF CASPOFUNGIN 
POSTUPAK I INTERMEDIJERI ZA SINTEZU KASPOFUNGINA
Hot steel strip particularly suited for the production of electromagnetic lamination packs 
VRUĆE VALJANE MAGNETSKE ČELIČNE TRAKE POSEBNO POGODNE ZA PROIZVODNJU ELEKTROMAGNETSKIH PAKETA
NEW BENZIMIDAZOLE DERIVATIVES 
NOVI DERIVATI BENZIMIDAZOLA
,2,3,4-TETRASUBSTITUTED INDOLE FOR THE TREATMENT OF RESPIRATORY DISEASES 
,2,3,4-TETRASUBSTITUIRANI INDOL ZA LIJEČENJE RESPIRATORNIH BOLESTI
Dry granulated composition comprising emtricitabine and tenofovir DF 
SUHA GRANULIRANA KOMPOZICIJA KOJA SADRŽI EMTRICITABIN I TENOFOVIR DF
SYNERGISTIC MIXTURES OF A ANTHRANILAMIDE INVERTEBRATE PEST CONTROL AGENTS 
SINERGISTIČKE SMJESE ANTRANILAMIDNIH SREDSTAVA ZA KONTROLU ŠTETOČINA BESKRALJEŽNJAKA
Injectable liquid paracetamol formulation 
INJEKTIBILNE TEKUĆE FORMULACIJE PARACETAMOLA
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain 
HETEROARIL-TETRAHIDROPIRIDIL SPOJEVI KORISNI ZA LIJEČENJE ILI PREVENCIJU BOLI
PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES 
DERIVATI PIRAZOLA KAO INHIBITORI RECEPTORSKIH TIROZIN KINAZA
AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE 
AMINOFENIL DERIVATI KAO NOVI INHIBITORI HISTONSKIH DEACETILAZA
SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE 
SUPSTITUIRANI DERIVATI PROPENIL PIPERAZINA KAO NOVI INHIBITORI HISTONSKE DEACETILAZE
Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level 
KOMBINACIJSKA TERAPIJA ZA LIJEČENJE DIJABETESA I STANJA POVEZANIH S NJIM, TE ZA LIJEČENJE STANJA KOJA SE POBOLJŠAVAJU POVEĆANJEM NIVOA GLP-1 U KRVI
BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX 
DERIVATI BENZIMIDAZOLA I NJIHOVA UPORABA ZA MODULACIJU GABAA RECEPTORA
ALCOHOL-IN-OIL TYPE EMULSION COMPRISING A MULTIVALENT METAL SALT 
EMULZIJA TIPA ALKOHOL-U-ULJU KOJA SADRŽI VIŠEVALENTNU METALNU SOL
HAIR GROWTH INHIBITION 
INHIBICIJA RASTA DLAKA
ANIONIC HYRDOGEL MATRICES WITH PH DEPENDENT MODIFIED RELEASE AS DRUG CARRIERS 
MATRICA ANIONSKOG HIDROGELA S PH OVISNIM MODIFICIRANIM OSLOBAĐANJEM KAO NOSAČ LIJEKA
Inner boot, particularly for a sports shoe 
UNUTARNJA ČIZMA, POSEBNO ZA SPORTSKU CIPELU
Decoder for watering system 
DEKODER ZA SUSTAV ZA NAVODNJAVANJE
-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS 
-(((4-FENIL)-PIPERAZIN-1-IL)-ALKIL)-3-ALKIL-1,3-DIHIDRO-2H-INDOL-2-ON DERIVATI I SRODNI SPOJEVI ZA TRETIRANJE POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA
PROCESSES FOR PREPARING EPTIFIBATIDE AND PERTINENT INTERMEDIATE COMPOUNDS 
POSTUPCI ZA PRIPREMANJE EPTIFIBATIDA I ODNOSNIH INTERMEDIJERA
Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases 
KOMBINACIJA R,R-GLIKOPIROLATA, ROLIPRAMA I BUDESONIDA ZA LIJEČENJE UPALNIH OBOLJENJA
Use of modified cyclosporins for the treatment of HCV disorders 
UPORABA MODIFICIRANIH CIKLOSPORINA ZA LIJEČENJE HCV POREMEĆAJA
BELT CASTING OF NON-FERROUS AND LIGHT METALS AND APPARATUS THEREFOR 
REMEN ZA LIJEVANJE NEŽELJEZNIH I LAKIH METALA I UREĐAJ ZA TU SVRHU
INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS 
DERIVATI INDOLILA KAO MODULATORI X-RECEPTORA
METHOD OF TREATING DIGESTED SLUDGE 
POSTUPAK ZA TRETMAN DIGESTIRANOG MULJA
Compounds and methods for treating dyslipidemia 
SPOJEVI I POSTUPCI ZA LIJEČENJE DISLIPIDEMIJE
ANTITUMOR COMBINATION COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ANTIBODIES INHIBITING GROWTH FACTORS OR THEIR RECEPTORS 
PROTUTUMORSKA KOMBINACIJA KOJA SADRŽI SUBSTITUIRANE AKRILOIL DISTAMICINSKE DERIVATE I PROTUTIJELA KOJA INHIBIRAJU ČIMBENIKE RASTA ILI NJIHOVE RECEPTORE
SPRAY PREVENTION DEVICE 
UREĐAJ ZA SPRJEČAVANJE PRSKANJA
METHOD FOR ENZYMATIC PREPARATION OF (S)-3-CYANO-5-METHYLHEXANOIC ACID 
POSTUPAK ENZIMSKOG DOBIVANJA (S)-3-CIJANO-5-METILHEKSANSKE KISELINE
SYSTEM AND METHOD FOR INSPECTING AND SORTING MOLDED CONTAINERS 
SUSTAV I POSTUPAK PREGLEDAVANJA I SORTIRANJA OBLIKOVANIH SPREMNIKA
ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE 
IZOKINOLINSKI DERIVATI KAO INHIBITORI RO-KINAZE
PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS 
SPOJEVI PIROLOTRIAZINA KAO INHIBITORI KINAZE
PROTEASOME INHIBITORS AND METHODS OF USING THE SAME 
INHIBITORI PROTEASOMA I POSTUPCI ZA NJIHOVO KORIŠTENJE
Stabilised supersaturated solid solutions of steroidal drugs 
STABILIZIRANE SUPERZASIĆENE KRUTE OTOPINE STEROIDNIH LIJEKOVA
COMBINATION OF R,R-GLYCOPYRROLATE, ROLIPRAM AND BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES 
KOMBINACIJA R,R-GLIKOPIROLATA, ROLIPRAMA I BUDESONIDA ZA LIJEČENJE UPALNIH OBOLJENJA
A flexible cutting group for bush-cutters 
FLEKSIBILNI REZAČKI SKLOP NAPRAVE ZA REZANJE GUSTIŠA
PROCESS FOR PREPARING AN APPARATUS COMPRISING A GEL LAYER 
POSTUPAK ZA PRIPREMU UREĐAJA KOJI SADRŽI SLOJ GELA
SYSTEM AND METHOD FOR PROCESSING FORM MARKINGS 
SUSTAV I POSTUPAK ZA OBRADU OZNAKA U OBRASCU
MUTEINS OF FIBROBLAST GROWTH FACTOR 21 
MUTEINI ČIMBENIKA RASTA FIBROBLASTA 21
HYDROXAMATES AS THERAPEUTIC AGENTS 
HIDROKSAMATI KAO TERAPEUTSKI AGENSI
PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH ECTEINESCIDIN 743 
PEGILIRANI LIPOZOMALNI DOKSORUBICIN U KOMBINACIJI SA EKTEINESCIDINOM 743
HETEROARYL-TETRAHYDROPYRIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN 
HETEROARIL-TETRAHIDROPIRIDIL SPOJEVI KORISNI ZA LIJEČENJE ILI PREVENCIJU BOLI
DEVICE AND METHOD FOR THE PRODUCTION OF BIOLOGICALLY ACTIVE COMPOUNDS BY FERMENTATION 
UREĐAJ I POSTUPAK ZA PROIZVODNJU BIOLOŠKO AKTIVNIH SPOJEVA FERMENTACIJOM
MEMBRANE ELECTROLYTIC REACTORS SYSTEM WITH FOUR CHAMBERS 
SUSTAV MEMBRANSKIH ELEKTROLITIČKIH REAKTORA S ČETIRI KOMORE
FORMULATION OF A THIENOPYRIDINE PLATELET AGGREGATION INHIBITOR 
FORMULACIJA TIENOPIRIDINSKOG INHIBITORA AGREGACIJE TROMBOCITA
A device for producing a beverage from a capsule (24), comprises 
Uređaj za proizvodnju napitka iz čahure (24) kojisadržava-
A process for the preparation of vitamin K2 (MK - 7) comprising the culture of Bacillus subtilis mutant strain GN13/72 - DSM 17766 deposited on December 05, 2005 at the DSMZ. 
Postupak priprave vitamina K2 (MK - 7), naznačen time da obuhvaća mutanta kulture Bacillus subtilis soja GN13/72 - DSM 17766 položenog 5. prosinca 2005. u DSMZ.
Use of midostaurin or vatalanib for the manufacture of a medicament for treating a KIT dependent disease in a patient, which comprises: 
Spoj, naznačen time, da je formule A [image] za uporabu u liječenju KIT ovisnog oboljenja kod pacijenta, a koja obuhvaća:
Use according to Claim 2, wherein the mutant form of KIT is selected from the group consisting of K642E, Y823D, Del 550-558, Del 557-561, N822K and N822H and the inhibitor is vatalanib. 
Spoj u skladu sa zahtjevom 1, naznačen time, da je mutantni oblik KIT izabran iz skupine koju čine D816H, D816N, K642E, Y823D, Del 550-558, Del 557-561, N822K i N822H.
The use of a dark fruit selected from blackcurrant, cranberry, pomegranate or a mixture of two or more thereof, for the manufacture of an orally ingestable composition for the promotion of health in a mammal characterised in that the dark fruit has a prebiotic effect. 
Upotreba tamnog voća, kojeg se bira između brusnice, crnog ribiza, nara ili smjese od dvoje ili više njih, u proizvodnji pripravka za oralni unos, za poticanje zdravlja kod sisavca, naznačena time što tamno voće ima prebiotički učinak.
Use as claimed in claim 1 wherein the dark fruit is in the form of fruit juice. 
Upotreba u skladu s patentnim zahtjevom 1, gdje tamno voće je u obliku voćnog soka.
The transdermal delivery device of claims 1-3, wherein the microspheres further comprise a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (∑-caprolactones), polyanhydrides, albumin, blends and copolymers thereof and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da mikrosfere nadalje sadrže polimer odabran iz skupine koja se sastoji od poliestera, polietera, poli (ortoestera), polisaharida, ciklodekstrina, citosana, poli (Σ-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera i njihovih smjesa.
The transdermal delivery device of claims 1-3, wherein the microspheres consist essentially of the opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (∑-caprolactones), polyanhydrides, albumin, blends and copolymers thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da se mikrosfere u osnovi sastoje od opioidnog antagonista i polimera odabranog iz skupine koja se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, citosana, poli (Σ-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera.
The transdermal delivery device of claim 1, where the matrix comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber- like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene vinyloxyethanol copolymer, silicones (e.g., silicone copolymers such as polysiloxane-polymethacrylate copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je sloj koji sadrži lijek matrični sloj, i da matrica poželjno sadrži materijal odabran iz skupine koja se sastoji od polietilena, polipropilena, etilen/propilen kopolimera, etilen/etilakrilat kopolimera, etilenvinil acetatnih kopolimera, silikona, gume, sintetičkih homo-, ko- ili blok polimera sličnih gumi, poliakrilinih estera i njihovih kopolimera, poliuretana, poliizobutilena, kloriranih polietilena, polivinilklorida, vinil klorid-vinil acetat kopolimera, polimera polimetakrilata (hidrogel), poliviniliden klorida, poli(etilen tereftalata), etilen-vinil alkohol kopolimera, etilen-viniloksietanol kopolimera, silikona (npr. silikon kopolimera kao što su polisiloksan-polimetakrilat kopolimera), celuloznih polimera (npr. etil celuloze i estera celuloze), polikarbonata, politetrafluoroetilena i njihovih smjesa.
A transdermal delivery device comprising: 
Sredstvo za transdermalno davanje koje sadrži:
The transdermal delivery device of any one of claims 1 to 3, wherein the opioid antagonist becomes releasable if the transdermal delivery device is chewed, soaked, punctured, torn, or subjected to any other treatment which disrupts the integrity of the microspheres; and/or wherein the effect of the opioid agonist is at least partially blocked when the delivery device is chewed, crushed or dissolved in a solvent, or subject to any other treatment which disrupts the integrity of the microspheres, and administered orally, intranasally, parenterally or sublingually. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da se opioidni antagonist može osloboditi kada se sredstvo za transdermalno davanje žvače, namoči, probuši, cijepa ili bude predmetom bilo kakvog drugog postupka koji narušava integritet mikrosfera. Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je učinak opioidnog agonista barem djelomično blokiran kada se sredstvo za davanje žvače, zdrobi ili otopi u otapalu ili bude predmetom bilo kakvog drugog postupka koji narušava integritet mikrosfera, i kad je primijenjeno oralno, intranazalno, parenteralno ili sublingvalno.
The transdermal delivery device of any one of claims 1 to 8, wherein the transdermal delivery device is a device selected from the group consisting of a transdermal patch, a transdermal plaster, a transdermal disc, and a iontophoretic transdermal device. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da sredstvo za transdermalno davanje je sredstvo odabrano od grupe koja se sastoji od transdermalonog zavoja, transdermalnog flastera, tansdermalne pločice, i iontoforetskog transdermalnog sredstva.
each R2 is independently: 
svaki R2 je neovisno:
The compound of claim 1, wherein X is O, m is 0, p is 0, n is 0 and Ar1 is a pyridazinyl group or a pyridinyl group. 
Spoj prema zahtjevu 1, naznačen time da X je O, m je 0, p je 0, n je 0 i Ar1 je piridazinil skupina ili piridinil skupina.
The compound of claim 1 and 2, wherein Ar2 is a benzothiazolyl group, benzoimidazolyl group, or benzooxazolyl group. 
Spoj prema zahtjevu 1 i 2, naznačen time da Ar2 je benzotiazolil skupina, benzoimidazolil skupina, ili benzooksazolil skupina.
The compound of claim 7, wherein (R8)b is an iso -propyl group, a tert -butyl group or a -halo selected from the group of -F, -Cl, -Br and -I. 
Spoj prema zahtjevu 7, naznačen time da (R8)b je izopropil skupina, tert-butil skupina ili -halogen odabran iz skupine koja sadrži -F, -Cl, -Br i -I.
A composition comprising the compound or a pharmaceutically acceptable salt of the compound of anyone of claims 1 - 9 and a pharmaceutically acceptable carrier or excipient. 
Sastav, naznačen time da sadrži spoj ili farmaceutski prihvatljivu sol spoja iz bilo kojeg zahtjeva od 1 do 9 i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
Use of an effective amount of the compound or a pharmaceutically acceptable salt of the compound of anyone of claims 1 - 9 and optionally an effective amount of another therapeutic agent for the manufacture of a medicament for treating pain in an animal. 
Upotreba učinkovite količine spoja ili farmaceutski prihvatljive soli spoja iz bilo kojeg zahtjeva od 1 do 9 i opcionalno učinkovite količine druge terapeutske tvari, naznačena time da se upotrebljava za izradu lijeka za liječenje boli u životinje.
Use of an effective amount of the compound or a pharmaceutically acceptable salt of the compound of anyone of claims 1 - 9 and optionally an effective amount of another therapeutic agent for the manufacture of a medicament for treating an ulcer in an animal. 
Upotreba učinkovite količine spoja ili farmaceutski prihvatljive soli spoja iz bilo kojeg zahtjeva od 1 do 9 i opcionalno učinkovite količine druge terapeutske tvari, naznačena time da se upotrebljava za izradu lijeka za liječenje ulkusa u životinje.
Use of an effective amount of the compound or a pharmaceutically acceptable salt of the compound of anyone of claims 1 - 9 for the manufacture of a medicament for inhibiting VR1 function in a cell. 
Upotreba učinkovite količine spoja ili farmaceutski prihvatljive soli spoja iz bilo kojeg zahtjeva od 1 do 9, naznačena time da se upotrebljava za izradu lijeka za inhibiranje funkcije VR1u stanici.
An in-vitro method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of anyone of claims 1 - 9. 
In-vitro metoda za inhibiranje funkcije VR1 u stanici, naznačena tima da uključuje kontaktiranje stanice sposobne za ekspresiju VR1s učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja iz bilo kojeg zahtjeva od 1 do 9.
A kit comprising a container containing an effective amount of the compound or a pharmaceutically acceptable salt of the compound of anyone of claims 1 - 9. 
Pribor koji uključuje spremnik koji sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja iz bilo kojeg zahtjeva od 1 do 9.
collecting and drying the microparticles formed in step (b) wherein step (b) is carried out by emulsifying the emulsion prepared in step (a) in a coherent aqueous phase to obtain a w/o/w-double emulsion, wherein the coherent aqueous phase comprises an osmotic agent, wherein the osmolality of the coherent aqueous phase is higher than that of the aqueous inner phase. 
prikupljanje i sušenje mikrodijelova oblikovanih u koraku (b) pri čemu korak (b) se provodi emulzifikacijom emulzije pripremljene u koraku (a) i povezane vodene faze da bi se dobila w/o/w-dvostruka emulzija, pri čemu povezana vodena faza sadrži osmotski agens, pri čemu je osmolalnost povezane vodene faze viša od one vodene unutarnje faze.
A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 4. 
Farmaceutski pripravak, naznačen time, da obuhvaća farmaceutski prihvatljive nosače i kao aktivni sastojak terapeutski učinkovitu količinu spoja prema zahtjevima od 1 do 4.
A combination of an anti-cancer agent and a HDAC inhibitor as claimed in any of claims 1 to 4. 
Kombinacija, naznačena time, da sadrži anti-tumorski agens i inhibitor HDAC prema zahtjevima od 1 do 4.
A process for preparing a compound as claimed in claim 1, characterized by reacting an intermediate of formula (II) with an appropriate acid yielding a hydroxamic acid of formula (I), 
Proces za pripremu spoja prema zahtjevu 1, naznačen time, da intermedijer sa formulom (II) reagira sa odgovarajućom kiselinom, a to dovodi do nastanka hidroksamske kiseline sa formulom (I). [image]
preparing the compounds of formula (V-a) in a single step by reacting the intermediate of formula (VI), with 1,4-dioxane-2,5-diol and the appropriate boronic acid of formula (VII), wherein R1 is as defined above or 
pripremanje spoja sa formulom (V-a) u jednom koraku uz pomoć reakcije intermedijera sa formulom (VI) sa 1,4-dioksan-2,5-diolom te odgovarajućom boronskom kiselinom (VII), gdje R1 je definiran ranije ili [image]